Krystal Biotech Announces Topline Results From GEM-3 Pivotal Trial of VYJUVEK In Patients With Dystrophic Epidermolysis Bullosa; Co. Reports ‘Pivotal GEM-3 trial met its primary endpoint of complete wound healing at six-month timepoints’

by | Nov 29, 2021 | Extra Jobs | 0 comments

Submit a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.